Feature | January 28, 2013

Peripheral Vascular Market Expected to See Strong Market Growth

Wider awareness and new treatment technology expected to help boost patient volume

Millennium Research Group Peripheral Vascular Device Market Growth

January 28, 2013 — According to Millennium Research Group (MRG), increasing awareness and diagnosis of peripheral vascular disease (PVD) along with the introduction of improved next-generation devices will lead the United States peripheral vascular (PV) device market to grow strongly to reach $3.3 billion by 2017.

Lower extremity treatment will grow substantially, as physicians and device manufacturers continue to focus on the prevention of limb amputation. A variety of recent and upcoming device launches, including drug eluting stents (DES) and drug-coated balloons (DCB), as well as improvements in lower-extremity stents will provide physicians with more options for treating lower extremity peripheral artery disease (PAD).

Growth in the femoral-popliteal (fem-pop) indication will be particularly strong. Historically, concerns about stent fractures have restrained their use, but next-generation devices offer improved flexibility and strength to address this issue. For example, Covidien recently released its Protege EverFlex and Flexible Stenting Solutions released its FlexStent, while IDEV Technologies is anticipated to receive U.S. Food and Drug Administration (FDA) approval for use of the Supera Veritas stent in the fem-pop arteries before 2015.

Furthermore, continued adoption of and physician familiarity with chronic total occlusion (CTO) devices will allow for endovascular treatment of increasingly challenging lesions in these indications, driving overall procedure volumes. In addition to the large players, including Boston Scientific, C. R. Bard, Cordis, Covidien and Medtronic, this segment has attracted a number of niche competitors such as Avinger, Baylis Medical and Spectranetics; these companies will be likely acquisition targets for larger competitors looking to expand their lower-extremity PV offerings.

"Aortic stent grafts will be the strongest growing peripheral vascular device segment, spurred by continual device improvement efforts by manufacturers," said MRG Analyst Louise Murphy. "A number of new manufacturers have begun to enter the U.S. market, based on its favorable climate and the need for niche devices and innovations."

Smaller new competitors in the abdominal aortic stent graft segment include Endologix, Aptus Endosystems and TriVascular, with Lombard Medical and Bolton Medical expected to enter the market before 2017. Device innovations such as fenestrated grafts, low-profile devices and improved fixation mechanisms will help differentiate competitors and drive market growth.

MRG’s U.S. Markets for Peripheral Vascular Devices report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for peripheral vascular (PV) stents, percutaneous transluminal angioplasty (PTA) balloon catheters, chronic total occlusion (CTO) crossing devices, embolic protection devices (EPD), aortic stent grafts, synthetic surgical grafts, and PV accessory devices sold in the United States.

For more information: www.MRG.net, www.DecisionResourcesGroup.com

Related Content

radial access, transradial
Feature | Radial Access| May 27, 2016 | Dave Fornell
The use of transradial artery vascular access for percutaneous coronary intervention (PCI) in the United States has s
Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
cath lab, radiation exposure, glocoma
Feature | Radiation Dose Management| May 26, 2016 | Dave Fornell
May 27, 2016 — Radiation exposure to cath lab staff and physicians has seen growing concern in recent years, as the p
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
Overlay Init